Download PDF
Thromb Haemost 1989; 62(02): 681-685
DOI: 10.1055/s-0038-1646882
Original Article
Schattauer GmbH Stuttgart

Is It Possible to Reduce the Risk of Cardiovascular Events in Subjects Suffering from Intermittent Claudication of the Lower Limbs?

J P Boissel
Unité de Pharmacologie Clinique, Hôpital Neuro-Cardiologique, Lyon, France
,
J C Peyrieux
Unité de Pharmacologie Clinique, Hôpital Neuro-Cardiologique, Lyon, France
,
J M Destors
Unité de Pharmacologie Clinique, Hôpital Neuro-Cardiologique, Lyon, France
› Author Affiliations
Further Information

Publication History

Received 12 December 1988

Accepted after revision 03 April 1989

Publication Date:
30 June 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

This study meta-analysed randomized, double-blind, placebo controlled trials in patients with intermittent claudication of the lower limbs comparing ticlopidine to placebo in order to test the hypothesis that the drug, a pure antiplatelet agent, is able to reduce the incidence of thrombotic cardio-vascular events on atherosclerotic arteries in these patients. A highly significant reduction, from 9% to 3% (p ranging from 0.006 to 0.002), was observed for fatal or non-fatal cardio-vascular events in a total of 611 patients (301 with ticlopidine, 310 with placebo). The duration of follow-up ranged from 6 to 12 months. Side-effects, defined as withdrawal from study medication for any reason but death, cardio-vascular events or cancer, were 2.4 times more frequent in the ticlopidine treated patients as compared to placebo. We concluded that in this high risk population, prevention of cardio-vascular events is likely to be effective.

Keywords

Meta-analysis - Intermittent claudication - Antiplatelet agent - Cardiovascular risks
 

  • References

  • 1 Imparato AM, Kim GE, Davidson T, Crowley JG. Intermittent claudication: its natural course. J Cardiovasc Dis 1976; 34: 455-462
    PubMedSearch in Google Scholar
  • 2 Juergens JL, Barker NW, Hines EA. Arteriosclerosis obliterans: review of 520 cases with special reference to pathogenic and prognostic factors. Circulation 1960; 21: 188-195
    CrossrefPubMedSearch in Google Scholar
  • 3 Kallero KS. Mortality and morbidity in patients with intermittent claudication as defined by venous occlusion plethysmography. A ten-year follow up study. J Chron Dis 1981; 34: 455-462
    CrossrefPubMedSearch in Google Scholar
  • 4 Kannel WB, Shurtleff D. The natural history of arteriosclerosis obliterans. Cardiovasc Clin 1971; 3: 37-52
    PubMedSearch in Google Scholar
  • 5 Blombery PA. Intermittent claudication: an update on management. Drugs 1987; 34: 404-410
    CrossrefPubMedSearch in Google Scholar
  • 6 Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T. Fate in intermittent claudication: outcome and risk factors. Br Med J 1986; 293: 1137-1140
    CrossrefPubMedSearch in Google Scholar
  • 7 Saltiel E, Ward A. Ticlopidine, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222-262
    CrossrefPubMedSearch in Google Scholar
  • 8 Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. on behalf of the ACT Research Group. Multicenter Double-blind Study of Ticlopidine in the Treatment of Intermittent Claudication and the Prevention of its Complications. Angiology 1988; 39: 802-811
    CrossrefPubMedSearch in Google Scholar
  • 9 Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized trials. N Engl J Med 1987; 316: 450-455
    CrossrefPubMedSearch in Google Scholar
  • 10 Boissel JP, Blanchard J, Furberg C, Panak E, Peyrieux JC, Sacks H. On behalf of the Meta-analysis Cooperative Group. Considerations for the meta-analysis of randomized clinical trials: summary of a panel discussion. Controlled Clinical Trials. in press.
  • 11 Ellis DJ. Treatment of intermittent claudication with ticlopidine. Abstract addendum. Presented at the International Committee on Thrombosis and Haemostasis 32nd Annual Meeting and the Mediterranean League Against Thromboembolic Diseases. 9th Congress Jerusalem: 1–6 June 1986
    Search in Google Scholar
  • 12 Cloarec M, Caillard PH, Mouren X. Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs. Thromb Res 1986; suppl (Suppl. 06) 160
    PubMedSearch in Google Scholar
  • 13 Stiegler H, Hess H, Mietaschk A, Trampisch HJ, Ingrisch H. EinfluB von Ticlopidin auf die periphere obliterierende Arteriopathie. Dtsch Med Wochenschr 1984; 109: 1240-1243
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1955; 22: 719-748
    PubMedSearch in Google Scholar
  • 15 Fleiss JL. Statistical Methods for Rates and Proportions. Wiley; New York: 1973
    Search in Google Scholar
  • 16 Cochran WG. Some methods of strengthening the common X2 tests. Biometrics 1954; 10: 417-451
    CrossrefPubMedSearch in Google Scholar
  • 17 DerSimonian R, Laird NM. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177-188
    CrossrefPubMedSearch in Google Scholar
  • 18 Bulpitt CJ. Confidence intervals. Lancet 1987; i: 494-497
    PubMedSearch in Google Scholar
  • 19 Baptista J, Pike MC. Exact two-sided confidence limits for the odds ratio in a 2 × 2 table. Algorithm AS115. Appl Stat 1977; 26: 214-220
    CrossrefPubMedSearch in Google Scholar
  • 20 Stuart J, Aukland A, George AJ, Hurlow RA. Effect of platelet inhibition with ticlopidine on fibrinolytic activity in patients with atherosclerosis. Haemostasis July 1982; (suppl.): abstract 179
    PubMedSearch in Google Scholar
  • 21 Drouin P, Stoltz JF, Pointel JP, Verry M, Gaillard S, Voisin P, Debry G. Rheological and platelet abnormalities in diabetic peripheral arterial diseases. Their correction by an antiaggregating agent: ticlopidine. 12th World Congr Angiology. Athens: 1980. abstract 654
    Search in Google Scholar
  • 22 Klingemann HG, Egbring R, Havemann K. Effects of ticlopidine on beta-thromboglobulin and platelet-factor-4 levels in peripheral vascular disease. Abstracts 2nd European Conference on Clinical Haemorheology 1981; 190: 95
    PubMedSearch in Google Scholar